Semaglutide: Research Applications

Research Applications

Semaglutide has been investigated across a broad range of therapeutic areas beyond its FDA-approved indications, driven by the pleiotropic effects of GLP-1 receptor signaling throughout the body. The following areas represent active research programs with peer-reviewed evidence.[3]

🩺 Cardiovascular Risk Reduction

The landmark SELECT trial (n=17,604) enrolled overweight/obese adults without diabetes but with established cardiovascular disease. Semaglutide 2.4 mg/week reduced major adverse cardiovascular events (MACE) by 20% compared to placebo (HR 0.80, 95% CI 0.72–0.90), establishing cardiovascular benefit independent of diabetes status.[5] The earlier SUSTAIN-6 trial (n=3,297, T2D population) demonstrated a 26% MACE reduction.[3]

⚖️ Obesity and Weight Management

The STEP clinical trial program established semaglutide 2.4 mg/week as among the most efficacious pharmacological approaches to obesity management. In STEP 1 (n=1,961, obesity without T2D), participants achieved mean body weight loss of 14.9% at 68 weeks, versus 2.4% with placebo.[4] The STEP 4 extension trial demonstrated that continued semaglutide maintained weight loss, whereas discontinuation resulted in regain of approximately two-thirds of lost weight within one year.[10]

🫘 Chronic Kidney Disease

The FLOW trial (n=3,533), published in the New England Journal of Medicine in 2024, demonstrated that semaglutide 1 mg/week reduced the risk of kidney disease progression, dialysis, or death from kidney or cardiovascular causes by 24% in adults with T2D and chronic kidney disease (eGFR 50–75 mL/min/1.73m², UACR ≥300 mg/g). This was the first GLP-1 agonist to demonstrate renal protection in a dedicated kidney outcomes trial.[6]

🫀 Heart Failure

Research from the STEP-HFpEF trial (n=529) investigated semaglutide 2.4 mg/week in adults with heart failure with preserved ejection fraction (HFpEF) and obesity. Semaglutide produced significantly greater reductions in Kansas City Cardiomyopathy Questionnaire scores (KCCQ-CSS) and body weight compared to placebo, establishing a potential role in managing the growing HFpEF + obesity phenotype.

🧠 Neurological and Addiction Research

Preclinical and epidemiological data suggest GLP-1 receptor agonism may reduce addictive behavior through central reward pathway modulation. Studies using GLP-1R agonists in rodent models show reduced alcohol intake, opioid self-administration, and food reward behavior. Observational analyses using large healthcare databases have identified associations between semaglutide use and reduced substance use disorder diagnoses, prompting ongoing controlled trials.

🫁 Metabolic-Associated Steatohepatitis (MASH/NASH)

The ESSENCE Phase 3 trial (n=800+) is evaluating semaglutide 2.4 mg/week for MASH with significant fibrosis (F2–F3). Earlier Phase 2 data from Newsome et al. (NEJM, 2021) showed semaglutide significantly improved NASH resolution compared to placebo in 59 weeks (40% vs 17% at 0.4 mg dose), though without significant fibrosis improvement.[7]

😴 Obstructive Sleep Apnea

The SURMOUNT-OSA program for tirzepatide informed parallel research interest in semaglutide for OSA. Observational studies and the Pillai et al. retrospective analysis of insurance data found GLP-1 receptor agonist use associated with reduced OSA severity and CPAP discontinuation rates, driven primarily by weight reduction and upper airway fat depot mobilization.